Search

Research

To compare the developmental and behavioral outcomes of children experiencing an initial vaccine-proximate (VP) febrile seizure (FS) to those having a non-VP-FS (NVP-FS) and controls who have not had a seizure.

Research

In the absence of an established gold standard, an understanding of the testing cycle from individual exposure to test outcome report is required to guide the correct interpretation of SARS-CoV-2 reverse transcriptase real-time polymerase chain reaction (RT-PCR) results and optimise the testing processes.

Research

This article explores why governments do not respond to public compliance problems in a timely manner with appropriate instruments, and the consequences of their failure to do so. Utilising a case study of Italian vaccination policy, the article considers counterfactuals and the challenges of governing health policy in an age of disinformation. It counterposes two methods of governing vaccination compliance: discipline, which uses public institutions to inculcate the population with favourable attitudes and practices, and modulation, which uses access to public institutions as a form of control.

Research

This article outlines the potential impacts of the AstraZeneca vaccine safety concerns. It considers the relevant heuristics and values affecting patient decision making and proposes some practical strategies for effective communication by clinicians and governments. The recommendations have been collaboratively developed by members of the Collaboration on Social Science and Immunisation (COSSI) steering group.

Researchers from The Kids Research Institute Australia would like to understand more about respiratory syncytial virus (RSV) and how we can provide the best protection for kids.

Vaccine Trials Group with Sir Charles Gairdner Hospital is conducting a trial of a vaccine against Clostridium difficile infection (CDI) in at-risk individuals.

Researchers at The Kids Research Institute Australia are studying a new pneumococcal vaccine designed to provide a broader protection for 21 serotypes of the bacteria S. pneumoniae – 8 more serotypes than the current vaccine given to new babies.

Highlights from the VTG Laboratory in 2024

RSV Protect Study

News & Events

Research reveals that friendly bacteria may help reduce flu symptoms, offering new insights into potential treatments and enhancing our understanding of immune health.